Back to journals
Academic JournalOpen Access

CNS Spectrums

2 Papers Indexed in Blossom

Data updated

Research Footprint

CNS Spectrums has 2 tracked papers indexed in Blossom (2021–2025) from 13 authors, most often covering Ketamine and Esketamine, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Schizophrenia.

Published Papers

Paywallindividual

Esketamine nasal spray versus quetiapine XR in adults with treatment-resistant depression: a secondary analysis of the ESCAPE-TRD randomized clinical trial

In a secondary analysis of ESCAPE-TRD (n=636), esketamine nasal spray plus an oral antidepressant, dosed according to US prescribing information, produced significantly higher remission rates from week 8 to week 32 and greater, earlier reductions in MADRS scores (from day 8) than quetiapine XR, with fewer discontinuations due to adverse events.

Published
Journal
CNS Spectrums
Authors
McIntyre, R. S., Mattingly, G., Godinov, Y., Buyze, J., Turkoz, I., Cabrera, P., Patel, M., Martinez, L., Himedan, M., Lopena, O.
Paywallmeta

Long-Term Efficacy of Combination Therapy of Transcranial Magnetic Stimulation with Ketamine for Patients with Treatment-Resistant Depression

This retrospective review (n=28) investigated the clinical benefits of combining two therapies, repetitive transcranial magnetic stimulation (rTMS) and ketamine infusion (together CTK), for patients with treatment-resistant depression (TRD). The review found that all 28 patients experienced significant and enduring (two years) decreases in their depressive moods post the CTK therapy. The review also called for further research into method optimization and randomised controlled trials.

Published
Journal
CNS Spectrums
Authors
Best, S. R. D., Pavel, D. G., Haustrup, N.

Quick Facts

Papers Indexed
2
h-Index
94
Open Access
Yes
Publisher
Cambridge University Press
Country
United Kingdom
Website
Visit